Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PU-H71 HCl (Zelavespib HCl) is a novel Hsp90 inhibitor, a novel purine-based analog, and a radiosensitizer that may be a promising agent for CIRT. PU-H71 HCL shows antitumor activity in many preclinical models of malignancy. PU-H71 HCL has an inhibitory effect on the protein expression levels of Rad51 and Ku70, which may be associated with the double chain break repair in the homologous recombination pathway and non-homologous end-joining pathway.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 45,000 | |||
5 mg | 在庫あり | ¥ 99,000 | |||
10 mg | 在庫あり | ¥ 146,000 | |||
25 mg | 在庫あり | ¥ 226,500 | |||
50 mg | 在庫あり | ¥ 312,500 | |||
100 mg | 在庫あり | ¥ 420,000 | |||
500 mg | 在庫あり | ¥ 844,500 |
説明 | PU-H71 HCl (Zelavespib HCl) is a novel Hsp90 inhibitor, a novel purine-based analog, and a radiosensitizer that may be a promising agent for CIRT. PU-H71 HCL shows antitumor activity in many preclinical models of malignancy. PU-H71 HCL has an inhibitory effect on the protein expression levels of Rad51 and Ku70, which may be associated with the double chain break repair in the homologous recombination pathway and non-homologous end-joining pathway. |
別名 | PU-H71 HCl(873436-91-0 Free base), Zelavespib HCl |
分子量 | 548.83 |
分子式 | C18H22ClIN6O2S |
CAS No. | 2095432-24-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (81.99 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PU-H71 HCl 2095432-24-7 Cell Cycle/Checkpoint Cytoskeletal Signaling DNA Damage/DNA Repair Metabolism HSP DNA/RNA Synthesis PU-H71 HCl(873436-91-0 Free base) Zelavespib HCl Inhibitor inhibitor inhibit